Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. — StellaEarly Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(1 site)
China
The First People's Hospital of Jingzhou, Jinzhou, Hubei Last updated October 2024